



Molecular Research of Alzheimer's Disease

Guest Editor:

Dr. Lorenzo Falsetti

Department of Emergency
Medicine, Internal and Sub-
Intensive Medicine, Azienda
Ospedaliero-Universitaria
"Ospedali Riuniti", 60166 Ancona,
Italy

Deadline for manuscript
submissions:

closed (15 February 2022)

Message from the Guest Editor

Alzheimer's Disease represents a growing health concern. The classical neuropathogenetic model, based on brain amyloid plaque deposition, neurofibrillary tangles and cholinergic system dysfunction is undergoing reconsideration and integration in light of the failure of both amyloid-targeted and cholinesterase-inhibiting therapies. A better understanding of the relationships between the classical pathogenetic pathways and newer hypotheses are urgently required to guide future research and develop effective drugs. The role of risk factors and comorbidities, such as vascular diseases and diabetes mellitus, as well as neurovascular unit dysfunction, are suggesting the existence of newer molecular mechanisms that could represent potential targets for effective Alzheimer's Disease treatments. The aim of this Special Issue of Biomedicines is to provide an overview of the pathophysiologic role of newer and older molecular mechanisms of Alzheimer's Disease and to advance new insights for the development of new therapeutic approaches. Moreover, it will focus on newer candidate markers of disease onset and progression.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)